多肽IMA950/poly-ICLC疫苗在新诊断成人恶性星形细胞瘤患者中的安全性和免疫原性I/II期试验
这项I/II期试验在新诊断成人胶质母细胞瘤(n=16)和III级星形细胞瘤(n=3)患者中评估IMA950多肽疫苗联合poly-ICLC佐剂的安全性和免疫原性,主要终点为安全性和免疫原性。疫苗安全且耐受良好,优化配方后观察到多肽CD8和持续Th1 CD4 T细胞反应,胶质母细胞瘤患者中位总生存期为19个月。
要点
- IMA950/poly-ICLC疫苗在新诊断恶性星形细胞瘤患者中安全且耐受良好。
- 优化疫苗配方后观察到多肽CD8和持续Th1 CD4 T细胞反应。
- 胶质母细胞瘤患者中位总生存期为19个月。
核心结论
- 该临床试验利用细胞表面呈递抗原,为优化胶质瘤患者产生效应T细胞的疫苗提供了见解。
研究设计与样本
- I/II期研究纳入新诊断成人胶质母细胞瘤患者16例和III级星形细胞瘤患者3例,均接受放化疗后IMA950/poly-ICLC疫苗接种。
- 前6例患者接受IMA950皮内注射和poly-ICLC肌内注射,方案修订后IMA950与poly-ICLC混合后皮下注射(n=7)或肌内注射(n=6)。
- 主要终点为安全性和免疫原性,次要终点为总生存期、6个月和9个月无进展生存期以及疫苗特异性外周CD4和CD8 T细胞反应。
主要发现
- IMA950/poly-ICLC疫苗安全且耐受良好,4例患者出现脑水肿并快速恢复。
- 前6例患者中疫苗诱导的CD8 T细胞反应仅限于单一肽,且无CD4反应。
- 优化疫苗配方后,观察到多肽CD8和持续辅助性T1 CD4 T细胞反应。
- 整个队列中,对单一或多肽的CD8 T细胞反应分别见于63.2%和36.8%的患者。
- 胶质母细胞瘤患者中位总生存期为19个月。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Peptide vaccines offer the opportunity to elicit glioma-specific T cells with tumor killing ability. Using antigens eluted from the surface of glioblastoma samples, we designed a phase I/II study to test safety and immunogenicity of the IMA950 multipeptide vaccine adjuvanted with poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose) in human leukocyte antigen A2+ glioma patients. METHODS: Adult patients with newly diagnosed glioblastoma (n = 16) and grade III astrocytoma (n = 3) were treated with radiochemotherapy followed by IMA950/poly-ICLC vaccination. The first 6 patients received IMA950 (9 major histocompatibility complex [MHC] class I and 2 MHC class II peptides) intradermally and poly-ICLC intramuscularly (i.m.). After protocol amendment, IMA950 and poly-ICLC were mixed and injected subcutaneously (n = 7) or i.m. (n = 6). Primary endpoints were safety and immunogenicity. Secondary endpoints were overall survival, progression-free survival at 6 and 9 months, and vaccine-specific peripheral cluster of differentiation (CD)4 and CD8 T-cell responses. RESULTS: The IMA950/poly-ICLC vaccine was safe and well tolerated. Four patients presented cerebral edema with rapid recovery. For the first 6 patients, vaccine-induced CD8 T-cell responses were restricted to a single peptide and CD4 responses were absent. After optimization of vaccine formulation, we observed multipeptide CD8 and sustained T helper 1 CD4 T-cell responses. For the entire cohort, CD8 T-cell responses to a single or multiple peptides were observed in 63.2% and 36.8% of patients, respectively. Median overall survival was 19 months for glioblastoma patients. CONCLUSION: We provide, in a clinical trial, using cell surface-presented antigens, insights into optimization of vaccines generating effector T cells for glioma patients. TRIAL REGISTRATION: Clinicaltrials.gov NCT01920191.
引用
- Migliorini D, Dutoit V, Allard M, et al. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. Neuro Oncol. 2019. PMID: 30753611. doi:10.1093/neuonc/noz040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。